Educational Videos 10

The investigators on their own trials, recorded at the congresses, plus the sessions and guideline explainers. Embedded with the publishers' agreement; the framing is ours. See also the podcasts.

40:52

New Horizons in Dyslipidaemia 2026, session 3: lipoprotein(a) (Libby, Cho, Kronenberg, Mora)

Peter Libby, Leslie Cho, Florian Kronenberg · February 2026

5:02

AHA 2025: Lp(a) and ASCVD, translating causal evidence into practice (Michelle O'Donoghue)

Michelle O'Donoghue · November 2025

14:04

ESC 2025: the focused update of the ESC/EAS dyslipidaemia guidelines, discussed (Roeters van Lennep, Van Spall)

Jeanine Roeters van Lennep, Harriette Van Spall · September 2025

3:24

ESC 2025: LipoaScreen, cascade screening for elevated Lp(a) in relatives (Jonas Brinck)

Jonas Brinck · September 2025

2:54

ACC.25: ALPACA, lepodisiran keeps Lp(a) down for 540 days after a single dose (Steven Nissen)

Steven E. Nissen · March 2025

3:40

AHA 2024: KRAKEN, oral muvalaplin lowers Lp(a) by up to 85 percent (Stephen Nicholls)

Stephen J. Nicholls · November 2024

5:29

AHA 2024: ALPACAR, zerlasiran in adults with elevated Lp(a) at high ASCVD risk (Steven Nissen)

Steven E. Nissen · November 2024

9:15

AHA 2023: lepodisiran, an extended-duration siRNA against Lp(a) (Steven Nissen with CardioNerds)

Steven E. Nissen, Maryam Barkhordarian · November 2023

14:29

AHA 2022: OCEAN(a)-DOSE, olpasiran cuts Lp(a) by more than 95 percent (Michelle O'Donoghue with CardioNerds)

Michelle O'Donoghue, Gurleen Kaur · November 2022

3:31

ACC.22: APOLLO, magnitude and duration of Lp(a) lowering with SLN360 (Steven Nissen)

Steven E. Nissen · April 2022